<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873807</url>
  </required_header>
  <id_info>
    <org_study_id>HIE-ALL-2013</org_study_id>
    <nct_id>NCT01873807</nct_id>
  </id_info>
  <brief_title>HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL</brief_title>
  <acronym>HITA</acronym>
  <official_title>An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intensified conditioning regimen allo-HSCT is based on a hypothesis of that intensifying
      condition with less-used drugs could overcome resistance,reduce tumor burden, and most
      importantly, spare enough time for slow-growing GVL effect following immune reconstitution to
      finally get rid of MRD and control the disease. Our previous trial of HDE-ALL-2011
      (NCT01457040) have confirmed the role of intensified conditioning allo-HSCT in adult ALL,
      resulting in significantly improved OS and EFS in comparison with previous standard TBI/CY2
      conditioning regimen(data not yet published). But at the same time, FA-TBI/CY2-VP16
      conditioning regimen was associated with high transplantation-related mortality (TRM), which
      might be attributed to excessive suppression on both bone marrow and immune. TT-ALL-HIE-2013,
      substituting FA with idarubicin, is aimed at maintaining anti-tumor effect with less
      cross-resistance and immune suppression and reducing TRM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It's well-known that the long-term outcome of adult acute lymphoblastic leukemia (ALL) lags
      far behind that of pediatric ALL,associated with different molecular cytogenetics make-up and
      treatment strategies. In search of an optimal regimen for pediatric ALL, comprehensive series
      of clinical trials of intensive chemotherapies have been conducted and lead to 80%-90%
      long-term survival. At the same time, pediatric-inspired chemotherapy protocol aslo yielded a
      charming result of 50-60% 3-year EFS in adolescent and young adult. In comparison with the
      leading role of intensive chemotherapy in pediatric ALL, allogeneic hematopoietic stem cell
      transplantation (allo-HSCT) plays an important role in treatment strategy of adult ALL.
      According to the state-of-art understanding of ALL, total therapy of ALL should consist of
      molecular-cytogenetics classification at diagnosis, minimal residual disease (MRD) monitoring
      and redefining risk classification during treatment, pediatric-inspired chemotherapy with
      high-dose Methotrexate/L-asparaginase during consolidation
      therapy,furthermore,risk/MRD-adapted allo-HSCT for high-risk and refractory/relapsed ALL.In
      pre-pediatric-inspired protocol era, allo-HSCT still represents the major role for improving
      the outcome of adult ALL, especially for high-risk and refractory/relapsed ALL. It's
      established that graft-versus-leukemia (GVL) effect was weak in ALL and patient shows poor
      response for donor-lymphocyte infusion (DLI). Intensified conditioning regimen allo-HSCT is
      based on a hypothesis of that intensifying condition with less-used drugs could overcome
      resistance,reduce tumor burden, and most importantly, spare enough time for slow-growing GVL
      effect following immune reconstitution to finally get rid of MRD and control the disease. Our
      previous trial of HDE-ALL-2011 (NCT01457040) have confirmed the role of intensified
      conditioning allo-HSCT in adult ALL, resulting in significantly improved OS and EFS in
      comparison with previous standard TBI/CY2 conditioning regimen(data not yet published). But
      at the same time, FA-TBI/CY2-VP16 conditioning regimen was associated with high
      transplantation-related mortality (TRM), which might be attributed to excessive suppression
      on both bone marrow and immune. TT-ALL-HIE-2013, substituting FA with idarubicin, is aimed at
      maintaining anti-tumor effect with less cross-resistance and immune suppression and reducing
      TRM.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-Free Survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplantation-Related Mortality</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>IDA-Etoposide Intensified Conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-IDA Conditioning</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDA</intervention_name>
    <description>Idarubicin: 15mg/m2/d: -8-&gt;-6d</description>
    <arm_group_label>IDA-Etoposide Intensified Conditioning</arm_group_label>
    <other_name>Idarubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>TBI: 4.5 Gy/d, -5d, -4d</description>
    <arm_group_label>IDA-Etoposide Intensified Conditioning</arm_group_label>
    <arm_group_label>Non-IDA Conditioning</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX</intervention_name>
    <description>CY:60mg/kg/d, -3d, -2d</description>
    <arm_group_label>IDA-Etoposide Intensified Conditioning</arm_group_label>
    <arm_group_label>Non-IDA Conditioning</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP-16</intervention_name>
    <description>VP-16: 15mg/kg, -2d, -1d</description>
    <arm_group_label>IDA-Etoposide Intensified Conditioning</arm_group_label>
    <arm_group_label>Non-IDA Conditioning</arm_group_label>
    <other_name>Etoposide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 16 years to 65 years;

          2. Diagnosis of acute lymphoblastic leukemia;

          3. Patient receives allo-HSCT;

          4. The informed consent form has been signed;

        Exclusion Criteria:

          1. Patient with severe cardiac dysfunction with less than 50% EF;

          2. Patient with severe lung dysfunction;

          3. Patient with more than 3 times ULN of serum ALT or AST levels, or with more than 2
             times ULN of serum TBIL level, or less than 40% of normal prothrombin time activity
             (PTA); or with more than 2 times the ULN of serum Cr;

          4. Patient with severe active infection;

          5. Patient with allergy history about suspected drug in conditioning regimen;

          6. Patient with other conditions considered unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematologym, Nanfang Hospital, Southern Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongsheng Zhou, PhD MD</last_name>
    <phone>86-20-62787883</phone>
    <email>hanson2008@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qifa Liu, MD</last_name>
    <phone>86-20-61641612</phone>
    <email>liuqifa628@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Union Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianda Hu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jianda Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou General Hospital of Guangzhou Military Command</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Xiao, MD</last_name>
      <email>jdxiao111@163.com</email>
    </contact>
    <investigator>
      <last_name>Yang Xiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suijin Wu, MD</last_name>
      <email>songwu55555@163.com</email>
    </contact>
    <investigator>
      <last_name>Suijin Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong No.2 Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510317</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing Zhang, MD</last_name>
      <email>zhqing@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Qing Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Zhou, MD PhD</last_name>
      <phone>86-20-62787883</phone>
      <email>hanson2008@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Qifa Liu, MD</last_name>
      <phone>86-20-61641612</phone>
      <email>liuqifa628@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hongsheng Zhou, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongjun Lin, MD</last_name>
      <email>lindongjun0168@163.com</email>
    </contact>
    <investigator>
      <last_name>Dongjun Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, 1st Guangzhou People Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunqing Wang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shunqing Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology-Hematology Center, 1st Affiliated Hospital, Guangzhou Medical Collgege</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huo Tan, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Huo Tan, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhua Li, MD PhD</last_name>
      <email>li_yuhua@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yuhua Li, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan People Hospital,Guangdong</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Xu, MD</last_name>
      <email>doctorxu@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaojun Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, 1st Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongrong Lai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yongrong Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Union Hospital, Huazhong Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Hu, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yu Hu, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Tongji Hospital, Huazhong Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou, MD PhD</last_name>
      <email>jfzhou@tjh.tjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jianfeng Zhou, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nfyy.com</url>
    <description>Website of Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idarubicin</keyword>
  <keyword>Etoposide</keyword>
  <keyword>HSCT</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

